Fentanyl Headlines and the Danger of False Precision
Numbers do not have to be fabricated to mislead; they can be technically accurate and still tell a false story when “detected” becomes “caused,” “involved” becomes “alone,” and a preliminary suspicion becomes a headline. That is the central warning of a new analysis by Dr. Lynn R. Webster, a leading physician and author specializing in pain management and addiction medicine. Webster points to a May 2026 emergency in Mountainair, New Mexico, where three people died in a home and investigators found fentanyl, para-fluorofentanyl, and methamphetamine. Eighteen first responders later reported symptoms such as nausea, coughing, and dizziness. Although officials said they were working merely “under the assumption” that fentanyl was responsible and noted that most evaluated responders had no symptoms, the event was widely described in headlines as an “apparent fentanyl exposure.” To a physician or a lawyer, the word “apparent” signals that causation has not been established. To most readers, however, it translates into a definitive cause. When the qualifier is truncated in news feeds, on social media, or in political speeches, it disappears entirely, converting an unproven inference into accepted fact.
The gap between expert language and public understanding has serious consequences. Webster argues that medical toxicologists have reported that clinically significant poisoning from incidental skin contact with fentanyl is extremely unlikely. Fentanyl is a potent opioid, but the fear of touching the drug has become so widespread that it has created panic, hazardous-material overreactions, and critical delays in administering CPR or naloxone to someone experiencing an overdose. Repeatedly writing “apparent fentanyl exposure” reinforces the belief that simply being near the drug can be fatal. That belief is not supported by the toxicological evidence, and it can have deadly effects when a witness hesitates to help a person who has collapsed from an overdose. Toxicologists have outlined safety steps and have warned that laws and protocols built on these false beliefs make the jobs of first responders harder, not safer. Instead of focusing on clinically appropriate response and medical care, responders may be forced to treat every scene as a hazmat event, delaying the very interventions that could save a life.
The same conversion of uncertainty into certainty plagues national mortality statistics. Webster explains that the International Classification of Diseases, known as ICD-10, uses the code T40.4 for “synthetic opioids other than methadone.” That code includes pharmaceutical fentanyl, illicitly manufactured fentanyl, fentanyl analogs, and even tramadol. It does not distinguish prescribed medications from illicit street drugs, and it does not establish whether fentanyl acted alone in causing a death. When federal researchers applied a more conservative calculation to separate these different sources, the estimated 2016 prescription-opioid death count fell by 47.3 percent, from 32,445 to 17,087. The actual number of people who died did not drop; rather, a flawed definition was corrected. Yet the original inflated number had already shaped headlines, influenced public opinion, and guided policy decisions. Webster argues that the persistence of these broad categories creates a false impression of precision in official records, and that the public is rarely told how much uncertainty remains in the numbers presented as straightforward facts.
Conflating illicit fentanyl with prescription opioids also distorts public policy. When deaths involving illicit supply are misclassified under broad prescription labels, policymakers respond by restricting legitimate medical prescribing. They impose rigid dose or duration limits, scrutinize clinicians who care for pain patients, and pressure stable patients to taper off medications. Webster notes that the Centers for Disease Control and Prevention, in its 2022 prescribing guideline, acknowledged that inflexible applications of its earlier guidance contributed to rapid tapers, abrupt discontinuation, patient abandonment, untreated pain, withdrawal, and psychological distress. Meanwhile, the needed focus and resources are diverted away from the illicit market shifts that actually drive the overdose crisis, such as fentanyl-contaminated stimulants, the need for naloxone distribution, expanded addiction and mental-health services, and the social conditions that fuel dangerous drug use. When the data blurs the line between a prescribed pain pill and an illicit fentanyl-laced counterfeit, the policy response targets patients and doctors instead of the drug supply. This does not make the public safer; it penalizes the most vulnerable and leaves the illicit market free to cause further harm.
Overlapping data categories further compound the confusion. A single death involving fentanyl, cocaine, and methamphetamine may be counted in all three drug categories in federal mortality statistics. Although the CDC warns that these categories should not be added together because one death can appear in multiple counts, headlines routinely report that fentanyl “caused” a certain number of deaths when the data only show that fentanyl was involved in the death or was detected after death. There is also the problem of hidden drivers, especially suicide and inadequately treated pain. Because classifying a drug death as intentional requires affirmative evidence, such as a suicide note or a documented threat, standard reporting defaults to “accidental” or “undetermined.” Researchers have estimated that true suicides may account for 20 to 30 percent of opioid overdose deaths, yet rigid database categories mask this complexity. Death certificates rarely record chronic pain, involuntary tapering, the loss of a prescriber, pharmacy refusal, worsening disability, or a patient’s turn to illicit drugs after medical care is disrupted. The absence of these drivers in a database does not erase their existence, and responsible reporting includes acknowledging these silent gaps rather than presenting raw mortality data as the complete story.
Webster does not minimize the genuine dangers of illicit fentanyl, but he warns that sensational law enforcement and media narratives spread because they are frightening. Stories of officers collapsing upon touching fentanyl, or fears of fentanyl-poisoned Halloween candy or contaminated paper currency, continue to circulate despite a lack of evidence. While illicit fentanyl poses real public health risks, unsubstantiated fear-mongering frightens responders, criminalizes people at overdose scenes, distorts public spending, and penalizes patients while the illicit market rages on. The solution, he argues, is precision. Journalists and public officials should adopt language that reflects what is actually known: “Fentanyl was detected” or “The cause remains under investigation.” They should distinguish illicit from pharmaceutical fentanyl whenever possible, and they should state clearly what the available data cannot establish. Uncertainty is not a flaw to be edited out; it is essential to the truth. When incomplete evidence is reported as certainty, policy targets the wrong people, the wrong drugs, and the wrong causes, and the reporting error itself fuels the crisis. Lynn R. Webster, a past president of the American Academy of Pain Medicine and a senior fellow at the Center for U.S. Policy, is the author of “The Painful Truth” and the forthcoming book, coauthored with Sarah Eichberg, “Deconstructing Toxic Narratives: Data, Disparities, and a New Path Forward in the Opioid Crisis.”